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1. Introduction 
We are currently developing steroid radioimmuno- 
assays [I ] which may be useful for monitoring foetal 
well-being in late pregnancy, as there is, at present, 
no single hormone assay which is entirely adequate 
for this purpose. Oestetrol (1 5hydroxyoestriol) offers 
a possible solution to this problem, as its production 
is almost entirely dependent upon a functioning 
foetal liver [2] and initial investigations have indeed 
indicated that the measurement of this steroid may 
provide a useful index of foetal viability [3,4]. The 
antisera used in these earlier investigations were raised 
against an antigen in which the steroid was linked 
through the three-position and showed reasonable 
specificity for the D ring; the cross-reaction for oestriol 
being 2.5% [S] . In this communication we report that 
more specific antisera may be obtained using an 
antigen in which the steroid is linked through the 
four-position. 
2. Materials and methods 
2.1. Reagents 
[6,7-3H]Oestetrol (50 Ci/mMole) was purchased 
from New England Nuclear. Non-labelled steroids 
were obtained from Steraloids Inc. Wilton, USA. 
General reagents were purchased from B.D.H. and all 
solvents were redistilled prior to use. Freund’s 
complete adjuvant was obtained from Difco Labora- 
tories. All samples were counted in S ml scintillant 
(NE 260, purchased from Nuclear Enterprises). 
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2.2. Preparation of Antigen 
To a solution of 4-aminobenzoic acid (0.137 g) in 
M hydrochloric acid (2 ml) at 5°C was added a 
solution of sodium nitrite (0.083 g) in water (1 ml) 
dropwise over ten min. The solution was left to stand 
for a further ten min at 5°C and then excess nitrous 
acid was removed by the addition of sulfamic acid. 
To a solution of oestetrol(O,O30 g) in methanol 
(7.5 ml), containing M sodium hydroxide (0.4 ml) 
under nitrogen at 0°C was added dropwise a solution 
of diazotised 4-aminobenzoic acid (0.3 ml), over 
fifteen min. The resulting Burgundy-coloured solution 
was stirred at 0°C for thirty min and then acidified 
(pH 5) with 0.1 M hydrochloric acid. The resulting 
suspension was centrifuged and the pale yellow 
supernatant discarded. The precipitate was washed 
with water (50 ml) in this manner several times. The 
final precipitate was separated by preparative thin- 
layer chromatography on silica plates, developed in 
ethyl acetate-cyclohexane-acetic acid-methanol 
(70:30:2: 1; by vol). Elution of the major coloured 
band, with tetrahydrofuran, gave 4-(4’carboxyphenyL 
azo)-oestetrol which separated from methanol as an 
amorphous red powder (0.024 g). A reproducible 
melting point could not be obtained because of 
decomposition above 250°C 
umay (Nujol); 3350 (broad; hydroxyls), 1695 
(carboxyl, 1605 (aromatic) and IS80 cm-’ (azo). 
x max (MeOH); 346 nm (E 1.4 X 104). 
6 (de-DMSO); 0.70 (3H, s, 1 %CHs), 6.78 
(lH,d,J=8 Hz,2-H),7.38(1H,d,J=8 Hz, 1-H) 
and 8.00 (4H, AA’ BB’ system, aromatic protons). 
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Mass spectrum of methyl ester (obtained by treatment 
of the acid with ethereal diazomethane): M’ 466 
(C26H30NZ06 requires 466). 
The derivatised steroid was coupled to bovine 
serum albumin using a method previously described 
[6] except that the crude product was purified only 
by dialysis against running water. The molar steroid: 
protein ratio of the conjugate was determined spec- 
trally to be 34: 1. 
2.3. Immunisation and characterization of antisera 
The conjugate was injected into four adult male 
New Zealand White rabbits (2.5 kg) as previously 
described, except that the initial dose was only 1 mg/ 
rabbit [7]. Blood was removed from the marginal 
ear vein ten days after the second and subsequent 
booster doses. 
The cross-reactions of various steroids which might 
compete with oestetrol for binding sites were measur- 
ed as previously described [7]. 
3. Results 
Blood samples removed after the second booster 
injection showed virtually no binding of labelled 
oestetrol. The characteristics of blood samples 
obtained following the third booster are shown in 
table 1. 
Table 1 
Specificity, working dilutions and sensitivity of 
anti-oestetrol+BSA antisera 
Steroid Antiserum 
Rl R2 R3 R4 
B2 B2 B2 B2 
Oestetrol 100 100 100 100 
Oestriol 0.7 0.7 0.35 0.38 
Oestradiol 0.02 <0.02 <0.02 0.09 
Oestrone <0.02 <0.02 <0.02 <0.02 
Testosterone <0.02 <0.02 <0.02 <0.02 
Dehydro- 
epiandrosterone <0.02 <0.02 <0.02 <0.02 
Progesterone <0.02 <0.02 <0.02 <0.02 
Working dilution 1:500 1:2500 1:lOOO 1:2500 
With these antisera 20 pg of oestetrol was detectable (disting- 
uishable from zero point with 99% certainty). Coding of 
Antisera: Rl-R4 refers to four individual rabbits and B2 refers 
to blood samples removed after the third booster injection. 
4. Discussion 
In the past we have raised specific antisera to 
oestrogens using haptens in which the steroid linked 
through the 6-position. The antisera thus obtained 
were highly specific and this was attributed to the 
fact that both of the structurally unique A and D 
rings were free to elicit the immune response [7,8] . 
However we were unable to apply this methodology 
to oestetrol because the D ring proved to be unstable 
to the strongly alkaline conditions required for 
deacetylation. We therefore chose to conjugate the 
steroid through the 4-position, as models indicated 
that this should leave all structurally unique hydroxyl 
functions available for immune recognition. In this 
context Katagiri et al. have obtained specific antisera 
for oestriol using a similar type of linkage [9]. 
Oestetrol was coupled to diazotised 4-aminobenzoic 
acid using a method similar to that described by Gross 
et al. [lo]. The n.m.r. spectrum corresponded closely 
to that of 4-(4’-carboxyphenylazo)-oestriol, indicating 
that it was indeed 4-linked [l 1 ] . The coupling con- 
stant for the two protons in the A ring is particularly 
important since it proves the assigned ortho relation- 
ship [12]. 
The antisera from all four rabbits only showed 
useful binding after fourteen weeks of injections 
which is an unusually long period in our experience 
[1,8]. Katagiri et al. [9] investigating the response to 
a similarly linked oestriol antigen also found very 
little binding in five out of six rabbits after twelve 
weeks of injections, suggesting that in the rabbit, 
antigens containing this type of linkage may generally 
give a slow immune response. 
The detection limit for oestetrol, using these anti- 
sera was sufficiently low (20 pg) to permit the assay 
of this steroid in 100 /..d of plasma at least as early as 
the twentieth week of gestation [3]. 
The described antisera were consistently more 
specific than those previously reported [5]. In normal 
pregnancy plasma the ratio oestriol: oestetrol is 
approximately 4: 1; so that with our antisera, cross- 
reacting oestriol would introduce an overestimation 
of oestetrol of around 1% and with existing antisera 
this overestimation is still only 10% [5] . However if 
oestetrol is indeed a better indicator of foetal distress 
than is oestriol then it is possible that in those cases 
of greatest clinical interest there may be an especially 
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high ratio of oestriol: oestetrol. In such cases the grea- 
test possible specificity would be essential. 
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